López, 72 patient HCQ late treatment study: 64% lower progression [p=0.02] https://c19p.org/lopez2
copied to clipboard
Telemedicine follow-ups for COVID-19: experience in a tertiary hospital
et al., Annals of Pediatrics, doi:10.1016/j.anpedi.2020.10.017
Retrospective 72 pediatric patients showing HCQ associated with a shorter duration of fever (p=0.023), less progression (p=0.016), and fewer return visits to the ER (p=0.017).
|
risk of progression, 64.3% lower, RR 0.36, p = 0.02, treatment 5 of 36 (13.9%), control 14 of 36 (38.9%), NNT 4.0.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
López et al., 11/2/2020, retrospective, Spain, Europe, peer-reviewed, 7 authors.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.